Diabetes Care, Vol 18, Issue 1 47-55, Copyright © 1995 by American Diabetes Association

ARTICLES

Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients

R Assan, C Perronne, D Assan, L Chotard, C Mayaud, S Matheron and D Zucman
Service de Diabetologie, Hopital Bichat, Paris, France.

OBJECTIVE--To assess the prevalence, presentation, and risk factors of pentamidine-induced dysglycemia. RESEARCH DESIGN AND METHODS--Blood glucose values were screened in 244 consecutive immunocompromised patients with Pneumocystis carinii pneumonia: 116 being treated with cotrimoxazole and 128 others with pentamidine. RESULTS--Two cotrimoxazole patients developed diabetes as a result of necrotizing pancreatitis (1.7%); the others remained euglycemic. Forty-eight pentamidine-treated patients (38.5%) developed severe glucose homeostasis disorders: hypoglycemia in 7, hypoglycemia and then diabetes in 18, and diabetes alone in 23 (P < 0.001 vs. the cotrimoxazole group). Hypoglycemia was early, sudden, often recurrent, and life-threatening, associated with inappropriately high insulin levels in plasma; the B-cell response to stimuli was poor. Of the 41 diabetic patients, 26 required insulin therapy; their plasma C-peptide levels were lower than normal, and the B-cell secretory responses to stimuli were poor. Islet cell antibodies, insulin antibodies, and insulitis were not detected. The pentamidine-treated dysglycemic patients differed from their euglycemic counterparts by higher pentamidine doses (P < 0.001), higher plasma creatinine levels (P < 0.001), and more severe anoxia (P < 0.05) and shock (P < 0.001). Most of them had received pentamidine mesylate parenterally (n = 36; 75%); six others received the isethionate salt and six exclusively pentamidine aerosols. CONCLUSIONS--Pentamidine-induced dysglycemic accidents are primarily due to inappropriate insulin release and toxicity to the islet B-cells. Drug accumulation due to excessive doses, iterative courses, and/or renal impairment is the determining risk factor.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. T. Cushion, P. D. Walzer, A. Ashbaugh, S. Rebholz, R. Brubaker, J. J. Vanden Eynde, A. Mayence, and T. L. Huang In Vitro Selection and In Vivo Efficacy of Piperazine- and Alkanediamide-Linked Bisbenzamidines against Pneumocystis Pneumonia in Mice. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2337 - 2343. [Abstract] [Full Text] [PDF]

				M. T. Cushion, P. D. Walzer, M. S. Collins, S. Rebholz, J. J. Vanden Eynde, A. Mayence, and T. L. Huang Highly Active Anti-Pneumocystis carinii Compounds in a Library of Novel Piperazine-Linked Bisbenzamidines and Related Compounds Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4209 - 4216. [Abstract] [Full Text] [PDF]

				J. C. Lee Altered Glucose Metabolism in HIV-infected Patients Treated With HAART Journal of Pharmacy Practice, February 1, 2004; 17(1): 80 - 86. [Abstract] [PDF]

				Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care, January 1, 2003; 26(90001): s5 - 20. [Full Text] [PDF]

				Z. T. Madhun, B. M. Arafah, and G. A. McComsey Impaired Glucose Tolerance in HIV-Infected Patients Ann Intern Med, November 2, 1999; 131(9): 715 - 716. [Full Text] [PDF]